| 0.735 -0.061 (-7.66%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.27 | 1-year : | 1.75 |
| Resists | First : | 1.09 | Second : | 1.5 |
| Pivot price | 0.86 |
|||
| Supports | First : | 0.43 | Second : | 0.35 |
| MAs | MA(5) : | 0.97  |
MA(20) : | 0.77 |
| MA(100) : | 0.8 |
MA(250) : | 1.31 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 27.3 |
D(3) : | 43.4 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 2.91 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRSN ] has closed above bottom band by 38.9%. Bollinger Bands are 270.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.78 - 0.78 | 0.78 - 0.79 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.73 - 0.73 | 0.73 - 0.74 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Wed, 06 Dec 2023
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth? - Simply Wall St
Tue, 05 Dec 2023
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints - PR Newswire
Tue, 05 Dec 2023
Neurosense Therapeutics Ltd (NRSN) has gained 42.95% Tuesday In Premarket Trading - InvestorsObserver
Mon, 04 Dec 2023
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints ... - PR Newswire
Mon, 04 Dec 2023
Will Neurosense Therapeutics Ltd (NRSN) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Fri, 01 Dec 2023
Where Does Neurosense Therapeutics Ltd (NRSN) Stock Fall in the Biotechnology Field After It Has Gained 75.00% This Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 36.8 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 234 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.6 % |
| Return on Equity (ttm) | -300.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.79 |
| PEG Ratio | 0 |
| Price to Book value | -36.75 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|